BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30655277)

  • 1. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness
    Maltais F; Aumann JL; Kirsten AM; Nadreau É; Macesic H; Jin X; Hamilton A; O'Donnell DE
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30655277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
    Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
    Kawachi S; Fujimoto K
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
    Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E; Brusselle GG; Joos GF
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M; Minakata Y; Motegi T; Ueki J; Gon Y; Seki T; Anzai T; Nakamura S; Hirata K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1407-1419. PubMed ID: 29750027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium
    Beaulieu J; Jensen D; O'Donnell DE; Brouillard C; Tracey L; Vincent S; Nadreau É; Bernard E; Bernard S; Maltais F
    Ther Adv Respir Dis; 2020; 14():1753466620939507. PubMed ID: 32663102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.
    O'Donnell DE; Casaburi R; Frith P; Kirsten A; De Sousa D; Hamilton A; Xue W; Maltais F
    Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28424359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study Design of VESUTO
    Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
    Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
    Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
    Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
    Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
    Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
    Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
    Buhl R; Maltais F; Abrahams R; Bjermer L; Derom E; Ferguson G; Fležar M; Hébert J; McGarvey L; Pizzichini E; Reid J; Veale A; Grönke L; Hamilton A; Korducki L; Tetzlaff K; Waitere-Wijker S; Watz H; Bateman E
    Eur Respir J; 2015 Apr; 45(4):969-79. PubMed ID: 25573406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.